netFormulary Coastal West Sussex NHS
Local Health Economy Formulary  

Welcome to the Coastal West Sussex Local Health Economy Formulary

If the product you search for is not found, it is currently non-formulary, and should not be routinely prescribed.

Useful Links

Effective Shared Care Agreements (ESCAs) Adult nutrition guidance Antibiotic Guidelines
Area Prescribing Committee (APC) CWS formulary application forms NICE Technology appraisals adherence checklist
Patient Resources Keeping Tabs Newsletter Infant Feeding Guidelines
Specials Guidance

Policies, Guidelines and Pathways

CWS CCG Website
Continence Formulary Dressings Formulary Blue Coding – Information sheets
Prescribing Quality Review Scheme (PQRS) National Reporting and Learning System (NRLS) Sussex Partnership Foundation Trust (SPfT) Link
Medicines Supply Updates Medicines Safety Information Self Care
Individual Funding Requests Download net formulary from Apple IOS Store Google Play net formulary


News Feed

December 2018 - Community Nurses collecting and transporting injectable medicines:

  • Until now, community nurses have been collecting prescribed injectable medicines and transporting them to the patient's home for administration. Due to workload pressures, it was agreed at the November 18 APC meeting that going forward, these items should be prescribed, dispensed and delivered along with patient's other medications, so they are already at the patient's home when the nurse visits. 

November 2018 - Shortage of Bricanyl® Turbohaler:

  • Astra Zeneca UK Ltd, the manufacturer of Bricanyl® Turbohaler® have informed healthcare professionals that they are currently experiencing an interruption to normal supplies. This is resulting in a temporary stock shortage and although some stock will be available in December 2018  the stock shortage is unlikely to fully resolve until end of January 2019. UKMi memo

October 2018 - Reclassification of gabapentinoids:

  • Following a public consultation and advice from the Advisory Council on the Misuse of Drugs, from April 2019 pregabalin and gabapentin will become controlled drugs and be placed under Schedule 3 of the Misuse of Drugs Regulations 2001 and Class C of the Misuse of Drugs Act 1971. Prescriptions of pregabalin and gabapentin will be limited to 30 days’ treatment, repeat prescriptions will not be issued and any prescription must be dispensed with 28 days. Link to Gov.Uk statement

September 2018 - Availability of EpiPen 0.3mg and EpiPen JR 0.15mg Adrenaline Auto-Injectors:

EpiPen and EpiPen Junior (adrenaline auto-injector devices) will be subject to limited availability for the remainder of 2018.  The manufacturer (Mylan) are currently out of stock of EpiPen Junior, with continued interruptions in supply anticipated in the coming months.
Supply disruption alert from the Department of Health and Social Care.

  • There is currently a temporary unavailability of EpiPen JR 0.15mg auto-injectors. Please use an alternative adrenaline auto-injector, though the patient or carer will need to be trained on how to administer the new auto-injector.
  • There is currently limited stock availability of the EpiPen 0.3mg auto-injectors. There are short dated stocks (Feb 2019) which community pharmacies can order through their usual channels. Stock with a longer expiry date is limited to two auto-injectors per prescription and community pharmacies should refer to the instructions within the link below.    27th September 2018 Update - EpiPen and EpiPen Junior 

August 2018 - Rifaximin for treating hepatic encephalopathy:

  • The recoding of Rifaximin (Targaxin®) tablets on the CWS formulary from RED to BLUE was agreed at the July 2018 APC meeting. A Rifaximin (Targaxin®) blue coding information sheet is now available to access on the CWS website and the CWS local health economy formulary.

July 2018 - Thickening agents:

  • Following an NHS England safety alert, all starch based thickening agents have now been coded BLACK for new initiations, due to safety concerns. Prescribing for patients already established on starch based products should remain unchanged, but any new patients being initiated on thickening agents should be prescribed gum based preparations.


>>> more news


The Coastal West Sussex local health economy formulary is the output of processes to support the managed introduction, utilisation or withdrawal of healthcare treatments in Coastal West Sussex. It is managed through the Coastal West Sussex Area Prescribing Committee and applies to all prescribers across the local health economy including Coastal West Sussex Clinical Commissioning Group, Western Sussex Hospitals NHS Foundation Trust, Sussex Partnership NHS Foundation Trust and Sussex Community NHS Trust.

The formulary is now up to date with respect to all the traffic light document information as well as the following currently ratified full BNF therapeutic chapters:

-Musculoskeletal and joint diseases
-Low Molecular Weight Heparins
-Ear, nose, and oropharynx

The following sections have been ratified by CWS APC but are only available as standalone documents under the useful links (supporting formulary documents) currently:

-Oral Nutrional Supplements

All NICE positively appraised medicines are automatically included within the formulary (where clinically appropriate) and these can be accessed via the NICE technology appraisal adherence checklist link above. These medicines are available for clinicians to prescribe, should they choose to, in a way that supports safe and clinically appropriate practice. Prescribing responsibility is defined within the traffic light system.

The technology in a NICE technology appraisal may not be the only treatment for a particular condition. If a NICE technology appraisal recommends use of a technology, it is as an option for the treatment of a disease or condition. This means that the technology should be available for a patient who meets the clinical criteria set out in the guidance, subject to the clinical judgement of the treating clinician. The NHS must provide funding and resources when the clinician concludes and the patient agrees that the recommended technology is the most appropriate to use, based on a discussion of all available treatments

The Medicines Management team are always happy to receive any feedback on the formulary. Please use the feedback button at the top of the page if you wish to contact us in relation to the formulary.

Every care has been taken in the compilation and publication of the content on our website. However, Coastal West Sussex Area Prescribing Committee (and its consituent NHS members) will not be held responsible for any loss, damage or inconvenience caused as a result of any inaccuracy or error within these pages.

Please note that all material in this site is aimed at healthcare professionals. Members of the public seeking advice on any medicine-related matters are encouraged to contact NHS 111 or speak with their GP, pharmacist or nurse.

Links are provided for information and convenience only. We cannot accept responsibility for the sites linked to, or the information found there. A link does not imply an endorsement of a site; likewise, not linking to a particular site does not imply lack of endorsement. Links to NHS member organisational policies or guidelines may not be accessible from all locations

We cannot accept any responsibility for any loss, disruption or damage to your data or your computer system that may occur while using material derived from this website.

   Visits = 269194
   Last updated: 17/01/2019 08:32:28
    Download net formulary from Apple IOS Store  Google Play net formulary